Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company University of Pennsylvania
DescriptionChimeric antigen receptor (CAR)-modified autologous T cells directed against mesothelin
Molecular Target Mesothelin
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
PartnerNovartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today